Petvivo Hldgs Inc Stock Price, News & Analysis

Digital Landia and PetVivo Holdings (OTCQB: PETV) have announced the launch of an invite-only MVP (minimum viable product) of Agentic.Pet, an autonomous pet artificial intelligence ecosystem. The platform, officially launched on May 23, 2025, is entering a stress-testing and debugging phase with select early adopters.

The MVP includes AI agents for veterinary diagnostics, behavioral analysis, and nutritional advising. Upcoming enhancements will feature pet facial recognition and specialized AI agents for blood tests, urine analysis, and radiological imaging. Access is currently limited to pet industry professionals and tech enthusiasts through an invite code system available at www.agenticpet.io.

PetVivo Holdings (OTCQB: PETV) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference, scheduled for May 14, 2025, at The Plaza Hotel in New York City. The company's CEO, John Lai, will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. ET. Investors and stakeholders interested in scheduling meetings can contact John Perez at D. Boral Capital.

PetVivo Holdings (OTCQB: PETV) has signed a distribution agreement with Eq Especialidades to market and distribute Spryng™ with OsteoCushion™ technology throughout Mexico, effective April 1, 2025.

Spryng™ is an intra-articular injectable veterinary medical device containing sterilized, extra-cellular matrix microparticles. The technology works by adsorbing onto animal joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics. It aids in managing noninfectious joint pain conditions including joint instability, degenerative joint disease, and osteoarthritis.

This strategic partnership aims to expand PetVivo's presence in the Mexican animal health market, targeting both equine and companion animal segments.

PetVivo Holdings (OTCQB: PETV) has secured a $5 million equity financing through a Series B Convertible Preferred Stock offering. The company received an initial $600,000 on March 26, 2025, with the remaining $4.4 million expected within 60 days.

The funds will support the commercialization of two key products: SPRYNG® with OsteoCushion® Technology, an intra-articular injectable veterinary device using sterilized extra-cellular matrix microparticles for joint pain management, and Precise PRP®, an off-the-shelf platelet-rich plasma product for veterinary use.

Precise PRP® is notable for being leucoreduced and containing 4 billion platelets per vial at 500,000 platelets per microliter concentration, requiring no blood draw or centrifugation for administration in dogs and horses.

PetVivo Holdings (OTCQB: PETV) has formed a strategic alliance with Digital Landia Corp. to integrate pet healthcare with AI technology. The partnership involves PetVivo exchanging $150,000 in restricted common stock for a 2% equity stake in Digital Landia and receiving 3 million Digital Landia tokens.

The collaboration centers on Pet AI, a platform that analyzes animal behavior with 97% accuracy through vocalizations, body language, and physiological signals. PetVivo's products, including SPRYNG® with OsteoCushion® Technology and Precise PRP®, will be exclusively promoted when the AI detects joint-related afflictions in pets.

The platform offers a freemium model with basic translation features and a $9.99/month subscription tier. The partnership targets a significant market, including 900 million dogs worldwide (25% with arthritis), 370 million cats, and 60 million horses, positioning PetVivo's joint treatment solutions within an AI-driven pet care ecosystem.

PetVivo Holdings (OTCQB: PETV) announced its participation in the Western Veterinary Conference (WVC) from March 2-5, 2025, at the Mandalay Bay Convention Center in Las Vegas. The company will showcase two key products: SPRYNG® with OsteoCushion® Technology, an intra-articular injectable veterinary device using sterilized, extra-cellular matrix microparticles for joint pain management, and PrecisePRP®, a novel off-the-shelf platelet-rich plasma product.

PrecisePRP® is notable for being leucoreduced, allogeneic, and requiring no blood draw or centrifugation, offering consistent dosing of 4 billion platelets per vial. The WVC, hosting over 15,000 participants, provides PetVivo an important platform to demonstrate these innovative solutions for osteoarthritis management in equine and companion animals.

PetVivo Holdings (OTCQB: PETV) reported fiscal Q3 2025 results with revenues of $583,000, up 191% sequentially but down 2% year-over-year. Distributor network sales reached $545,000, up 222% sequentially. The company maintained a strong gross margin of 89.5%, while operating loss improved by $375,000 to $1.8 million.

The company's lead product, Spryng with OsteoCushion Technology, is now used in over 800 veterinary clinics across all 50 states. PetVivo is shifting focus to include the larger companion animal market alongside its equine business, leading to sales force realignment. The company projects fiscal 2025 revenue of approximately $1.1 million, representing 10% growth.

Cash position stood at $29,000 as of December 31, 2024, but improved to $418,000 following a recent $1.1 million capital raise. Net cash used in operating activities decreased 31% compared to the previous year, reflecting improved operational efficiency.